LumiThera highlights improved AMD trial results

LumiThera has shared new topline data from its extension trial for the Valeda Light Delivery System, a treatment for dry age-related macular degeneration (AMD). The extension study demonstrated that the treatment’s efficacy can be extended from 24 months to 4.5 years, showing that longer and earlier interventions provide increased benefits. Valeda, FDA-authorized in November 2024, uses photobiomodulation to stimulate retinal cells and delay disease progression.

The LIGHTSITE IIIB study enrolled 75 subjects, with treatments consisting of nine sessions over three to five weeks. After 13 months, over 60% of subjects showed a vision improvement of over one line on an eye chart. This study marks Valeda as the first FDA-authorized non-invasive therapy capable of improving vision in dry AMD patients, with extended benefits out to 4.5 years. Dry AMD is a leading cause of vision loss in people aged 60 and older.

11-05-2025